Clinical trials: Atopic Dermatitis, Unspecified
Atopic Dermatitis, Nature, Human
Sand Play - the Effect of Biodiversity Exposure on Atopic Dermatitis
The prevalence of atopic dermatitis has increased along with urbanization and biodiversity loss. According to biodiversity hypothesis, the main reason is urban lifestyle and reduced contact to microbial diversity.
- Conditions
- Atopic Dermatitis, Nature, Human, Microbial Colonization, Immune System and Related Disorders
- Trial name
- BIWE (NCT06390696)
- Testing
- Microbial intervention
- Where
- 2 sites in Finland
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Natural Resources Institute Finland
Atopic Dermatitis
Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis
This is the first time PF-07242813 will be given to humans. The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07242813 in healthy participants and…
- Trial name
- NCT04668066
- Testing
- PF-07242813
- Where
- 7 sites in United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Pfizer
Normal Volunteers, Atopic Dermatitis (AD)
Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-3712 in healthy adults and patients with atopic dermatitis.
- Conditions
- Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Atopic Eczema/Dermatitis (Non-Specific)
- Trial name
- NCT07205081
- Testing
- ATTO-3712
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Attovia Therapeutics Inc
Allergic Asthma, Atopic Dermatitis
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL
Phase 1 study to evaluate the safety of MEDI4212.
- Conditions
- Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
- Trial name
- NCT01544348
- Testing
- Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous
- Where
- 7 sites in United States
- Volunteers
- 295 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Atopic Dermatitis
The Effect of Intervention and Mechanism of ICBT on Chronic Itching in Patients With Atopic Dermatitis
Objectives: The study subjects were 180 healthy people from the dermatology clinic of Xiangya Hospital of Central South University and the surroundingcommunity, including 120 AD patients (60 in the ICBT treatment group and 60 in…
- Trial name
- NCT05502848
- Testing
- Internet Cognitive Behavior Therapy
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Xiangya Hospital of Central South University
Atopic Dermatitis
Atopic Dermatitis: Sub-Saharan Africa vs. Central Europe
Many people are affected by atopic dermatitis (AD) worldwide. However, clinical studies on AD in Sub-Saharan Africa are rare and there is a lack of knowledge about possible differences in pathogenesis between European and African…
- Trial name
- NCT05363904
- Testing
- Observation
- Where
- 3 sites in Madagascar, Switzerland and 1 more
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Atopic Dermatitis
Skin Tape Transcriptome Methods in Children
This pilot study will evaluate new methods for the collection, storage, shipment, and RNA extraction of skin tape specimens from children with atopic dermatitis (AD) that will facilitate the multi-center SunBeam Birth Cohort…
- Trial name
- NCT04180644
- Testing
- Skin tape strips
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Jewish Health
Dermatitis, Atopic
Efalizumab for Moderate to Severe Atopic Dermatitis
The purpose of this study is to determine if Raptiva will have beneficial effects in the treatment of patients with moderate to severe atopic dermatitis.
- Trial name
- NCT00226057
- Testing
- Raptiva
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Atopic Dermatitis, Healthy
Assessment of Clinical, Biological and Biometrological Parameters in Adults Subjects With Atopic Dermatitis
In most recent years, the gut microbiome has been highlighted as a key player in the control of organs distant from the gut. Indeed, studies have raised evidence that gut microbiota exerts a control on various diseases including…
- Trial name
- NCT07017348
- Testing
- Clinical assessments, Biometrological measurements, Biological sampling
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermo Cosmetique
Dermatitis, Atopic
A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis
The purpose of this first-in-human (FIH) study is to assess the safety and tolerability, pharmacokinetics (PK), immunogenicity (IG) and pharmacodynamics (PD) of DCY636.
- Trial name
- NCT07604324
- Testing
- DCY636
- Where
- Japan
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Acne, Atopic Dermatitis
Sebum Metabolomics and Lipidomics for Clinical Applications
This study aims to develop a standardized workflow for sebum sampling and metabolomics/lipidomics analysis using Sebutape. A total of 200 participants will be recruited, including healthy individuals, patients with skin diseases…
- Conditions
- Acne, Atopic Dermatitis, Seborrheic Dermatitis, Psoriasis
- Trial name
- NCT07549828
- Testing
- Sebutape sampling, Bacitracin/Polymyxin B/Neomycin ointment (Yentuogin ointment)
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Healthy Participants, Atopic Dermatitis
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis.
- Trial name
- NCT06564389
- Testing
- PF-07832837
- Where
- 8 sites in United States, Poland
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Pfizer
Health Adult Subjects, Atopic Dermatitis (AD)
Study of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis
This is a Phase I/II, multicenter, randomized, double-blind, placebo-controlled study evaluating HXN6005 in healthy participants and patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT07782476
- Testing
- HXN6005
- Where
- China
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Helixon Biotechnology (Suzhou) Co., Ltd
Atopic Dermatitis
Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis
The primary objective of this trial is to investigate the safety and tolerability of LEO 138559 in healthy subjects and subjects with moderate to severe atopic dermatitis.
- Trial name
- NCT03514511
- Testing
- LEO 138559
- Where
- 3 sites in United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Itch
Role of Interleukin-13 Pathways on Pain and Itch Sensitivity
Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms.
- Trial name
- IL-13 (NCT06503510)
- Testing
- Histamine, Cowhage, bovine adrenal medulla (BAM8-22)
- Where
- 3 sites in Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Aalborg University
Atopic Dermatitis
Soothing and Barrier Restoration Activity of a Body Cream for Atopic Skin
Open clinical study to evaluate the soothing activity of a body cream to be applied once a day, mono-laterally at level of the antecubital fold and forearm, for an uninterrupted period of 1 month, by 22 adult volunteers, with…
- Trial name
- NCT03484897
- Testing
- P927 - LICHTENA DermAD CREMA CORPO
- Where
- Italy
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Derming SRL
Dermatitis, Atopic
Histamine Pharmacogenetics in Children With Atopic Dermatitis
The primary goal of the study is to investigate the impact of a common genetic polymorphism in a histamine detoxification enzyme that may well have a common role in regulating the expression of atopic dermatitis (AD) and other…
- Trial name
- NCT00277433
- Testing
- Buccal Swab
- Where
- 7 sites in United States
- Volunteers
- 751 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Atopic Dermatitis, Healthy Participants
A Study of BYN-001 in Healthy Adults and in Adults With Moderate to Severe Atopic Dermatitis
This first-in-human study evaluates BYN-001, a humanized IgG1 monoclonal antibody targeting interleukin-25 (IL-25), a cytokine implicated in atopic dermatitis.
- Trial name
- BYN-001-101 (NCT07746817)
- Testing
- BYN-001
- Where
- Australia
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Bionyra Pharma
Eczema/Atopic Dermatitis, Cancer
Patient Forward Access to Clinical and Technological Research: Genetic Influences on Cancer and Atopic Dermatitis
This Patient Forward study intends to conduct research to investigate potential genetic factors causing cancer and eczema/atopic dermatitis.
- Trial name
- PFACTR02 (NCT04362852)
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Boston Children's Hospital
Atopic Dermatitis
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)
This is a Phase 1, randomized, blinded, placebo controlled, single ascending dose (SAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).
- Trial name
- NCT07239947
- Testing
- BBT001
- Where
- 10 sites in China
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Bambusa Therapeutics